# What the first TRANSCEND diabetes trial measured

- Article ID: research-313
- Product: RETA GLP-3 (reta-glp-3-689, reta-glp-3-690, reta-glp-3-705, reta-glp-3-706)
- Canonical page: https://heritagebiolabs.com/research-library/articles/313-what-the-first-transcend-diabetes-trial-measured
- Product collection: https://heritagebiolabs.com/research-library/products/reta-glp-3
- Product page: https://heritagebiolabs.com/product/reta-glp-3-689
- Product page: https://heritagebiolabs.com/product/reta-glp-3-690
- Product page: https://heritagebiolabs.com/product/reta-glp-3-705
- Product page: https://heritagebiolabs.com/product/reta-glp-3-706
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held together by peptide bonds. They can engage receptors that affect how the body handles glucose. Retatrutide is an investigational peptide that acts at GIP, GLP-1 and glucagon receptors. The catalog’s “GLP-3” wording describes this entry rather than a receptor. The 2026 TRANSCEND-T2D-1 trial examined a specific group of adults with type 2 diabetes whose glucose was above target with diet and exercise alone. [1]

The trial randomized 537 participants to one of three retatrutide groups or placebo. The investigators recorded changes in HbA1c at 40 weeks. HbA1c measures how much glucose is attached to hemoglobin, giving an estimate of blood sugar exposure over the previous months. This differs from one fasting glucose test, which reflects the concentration at a particular time. HbA1c helped the researchers measure the effect of the tested assignments over the trial period. [1]

The three retatrutide groups had average HbA1c decreases of 1.69, 1.86 and 1.94 percentage points, compared with 0.81 percentage points with placebo. The differences from placebo ranged from 0.88 to 1.12 percentage points. It is important to keep both the change from baseline and the comparison with placebo in view. Some change also occurred in the placebo group. The randomized contrast estimates the difference associated with assignment to retatrutide under the study conditions. [1]

The study also measured weight and adverse events. An improvement on the glucose measure provides evidence for that outcome. Other measures describe separate parts of the experience, such as whether weight changed and which symptoms were reported during treatment. A 40-week study can establish a comparative result for the planned interval. It provides less information about rare adverse effects or complications that take years to develop. [1]

This trial enrolled people whose glucose management at baseline relied on diet and exercise. TRIUMPH-2 also enrolled people with type 2 diabetes but included many participants who already took glucose-lowering medicines and used weight change as the main outcome. These different designs help explain why diabetes research on one peptide may include more than one large trial. TRANSCEND-T2D-1 addresses glucose control under its own entry criteria and comparator. It does not establish an approved diabetes indication or provide a result for combinations that the investigators did not assign. [1, 2]

## Sources

1. H. S. Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet (publication 2026-06-06). <https://pubmed.ncbi.nlm.nih.gov/42250575/>
2. Virginia Bellido et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet (publication 2026-09-29). <https://pubmed.ncbi.nlm.nih.gov/42810372/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 063 - RETA GLP-3 and RETA IGF-1 LR3.docx; article 313; content SHA-256 2329d0e7357c9b7fda1e6c29b33014901329fa5568b3cdeeb11a533f7341343b.
